SAB Biotherapeutics’ SAB-185 moves to Phase 3 trial for Covid-19 treatment
Advancement to Phase 3 is a major milestone for SAB’s unique DiversitAb immunotherapy platform that produces fully human polyclonal antibodies without human donors
Advancement to Phase 3 is a major milestone for SAB’s unique DiversitAb immunotherapy platform that produces fully human polyclonal antibodies without human donors
Zydus' Apremilast tablets are indicated for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy
It is a recombinant nanoparticle protein-based vaccine
saRNA is a new platform for the development of medicines and vaccines which uses similar technology to mRNA but with the added ability to self-amplify, thereby expressing proteins for longer, resulting in higher protein levels per dose level
In India, almost all approved vaccines are packed in FIOLAX glass made by SCHOTT
These aprons utilise phase change materials that absorb, store and release heat for optimal thermal comfort
Ampion is directly administered by inhalation and it allows the drug to directly target and attenuate inflammation in the lungs
It becomes the first ophthalmology biosimilar to gain FDA approval in the United States
Surufatinib is the third potential new medicine discovered by the company to enter into clinical development in Japan
New Gibco AAV-MAX Helper Free AAV Production System helps reduce production costs and streamline the transition from research to clinical environments
Subscribe To Our Newsletter & Stay Updated